Management of Inflammatory CNV

Choroidal neovascularization in a patient after resolution of multiple evanescent white dot syndrome: A case report

“…16 Performing of photodynamic therapy (PDT) nowadays is uncommon for its possible adverse effects (choriocapillaris hypoperfusion, atrophy of retinal pigment epithelium, and increased subretinal edema followed by foveal thinning). [9][10][11] In case, we presented a peripapillary classic CNV after apparent resolving of MEWDS suddenly developed. There were no chorioretinal scars or atrophy at this region.…”

Favorable clinical outcome with intravitreal aflibercept treatment in a case with bilateral choroidal neovascular membrane and quiescent Vogt-Koyanagi-Harada syndrome

“…There is no clear standard of care for CNV management in inflammatory disorders. Steroids and immunosuppressives are often used in uveitis to reduce the inflammatory stimulus which seems to play a role in CNV formation, and also partly due to their antiangiogenic effect [ 8 ]. However, locally targeted therapy is often administered to treat the CNV in order to achieve an anatomically and visually superior outcome [ 1 ], [ 9 ], [ 10 ].…”

Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia

“…Steroids and immunosuppressives are generally used in uveitis to reduce the inflammatory stimulus which seems to play a role in CNV formation and also partly due to their antiangiogenic effect. 15 Anti-VEGF agents have also been used in addition to systemic therapy in eyes with inflammatory CNV in case reports and series. In a randomized study investigating the efficacy and safety of ranibizumab for the treatment of CNV due to uncommon causes in a group of 178 patients, 18 (15.1%) had postinflammatory type CNV and a single loading dose followed by a pro re nata regimen seemed to succeed statistically both in anatomic and visual outcome.…”